Total trials
198
Active
27
Phase 3
17
Total enrollment
88,448
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Empagliflozin 10 MG | — | — | — | — | — | 1 | |
| Application of T-lymphocytes | — | — | — | — | — | 1 | |
| Intracochlear application of VSF1.01 | — | — | — | — | — | 1 | |
| Bulevirtide | — | — | — | — | — | 1 |
Next readouts
- 2024-11-30
- 2026-10-28
- 2027-05
- 2027-11
Top conditions
- Lung Transplantation16
- Heart Failure5
- Heart Transplantation4
- Liver Cirrhosis4
- Complication of Surgical Procedure3
- Coronary Artery Disease3
- Bronchiolitis Obliterans3
- Septic Shock3
Frequently asked questions about Hannover Medical School
- How many clinical trials does Hannover Medical School have on ClinicalTrials.gov?
- Hannover Medical School is listed as the lead sponsor on 198 clinical trials in ClinicalTrials.gov, 27 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Hannover Medical School's trials are in Phase 3?
- 17 of Hannover Medical School's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Hannover Medical School focus on?
- Hannover Medical School's most-studied conditions on ClinicalTrials.gov are Lung Transplantation, Heart Failure, Heart Transplantation, Liver Cirrhosis, Complication of Surgical Procedure.
- When are Hannover Medical School's next clinical trial readouts?
- Hannover Medical School has 4 upcoming primary-completion readouts tracked here; the soonest is “Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)”, expected around 2024-11-30.